MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents
Dégradation de protéine ciblée de parp14 pour une utilisation en thérapieInfo
- Publication number
- MA56513A MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
- Authority
- MA
- Morocco
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56513A true MA56513A (fr) | 2022-04-27 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056513A MA56513A (fr) | 2019-06-19 | 2020-06-18 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220388985A1 (fr) |
| EP (1) | EP3986887A1 (fr) |
| JP (2) | JP2022537349A (fr) |
| KR (1) | KR20220024098A (fr) |
| CN (2) | CN120398840A (fr) |
| AU (1) | AU2020296063B2 (fr) |
| BR (1) | BR112021025645A2 (fr) |
| CA (1) | CA3142002A1 (fr) |
| MA (1) | MA56513A (fr) |
| SG (1) | SG11202112980TA (fr) |
| WO (1) | WO2020257416A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102835667B1 (ko) | 2017-12-21 | 2025-07-21 | 애브비 바이오테크놀로지 리미티드 | Parp14 억제제로서의 퀴나졸리논 |
| JP2024502467A (ja) * | 2021-01-08 | 2024-01-19 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ニンボリドアナログ及びその使用方法 |
| WO2022165118A1 (fr) * | 2021-01-29 | 2022-08-04 | Ribon Therapeutics, Inc. | Méthodes de traitement de maladies inflammatoires |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN117229224A (zh) * | 2022-06-07 | 2023-12-15 | 中国药科大学 | 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用 |
| EP4562007A1 (fr) | 2022-07-29 | 2025-06-04 | Abbvie Operations Singapore Pte. Ltd. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| TW202417435A (zh) | 2022-07-29 | 2024-05-01 | 美商律幫治療股份有限公司 | 用於治療之parp14之靶向蛋白質降解 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (fr) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | Dérivé de quinazolinone et son utilisation médicale |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| UA119870C2 (uk) * | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| AU2017367872B2 (en) * | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| EP3580212A4 (fr) * | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | Régulation de récepteurs d'antigènes chimériques |
| US20210154184A1 (en) * | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| KR102835667B1 (ko) * | 2017-12-21 | 2025-07-21 | 애브비 바이오테크놀로지 리미티드 | Parp14 억제제로서의 퀴나졸리논 |
-
2020
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/fr active Pending
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko active Pending
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/fr not_active Ceased
- 2020-06-18 CA CA3142002A patent/CA3142002A1/fr active Pending
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 AU AU2020296063A patent/AU2020296063B2/en active Active
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
-
2025
- 2025-04-02 JP JP2025061199A patent/JP2025102917A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021025645A2 (pt) | 2022-02-01 |
| JP2025102917A (ja) | 2025-07-08 |
| EP3986887A1 (fr) | 2022-04-27 |
| CN114206853A (zh) | 2022-03-18 |
| AU2020296063B2 (en) | 2026-01-29 |
| AU2020296063A1 (en) | 2021-12-23 |
| KR20220024098A (ko) | 2022-03-03 |
| WO2020257416A1 (fr) | 2020-12-24 |
| JP2022537349A (ja) | 2022-08-25 |
| SG11202112980TA (en) | 2021-12-30 |
| US20220388985A1 (en) | 2022-12-08 |
| CA3142002A1 (fr) | 2020-12-24 |
| CN120398840A (zh) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| EP3710002A4 (fr) | Agents de dégradation et dégrons pour dégradation protéique ciblée | |
| HUE062404T2 (hu) | Protein tirozin foszfatáz inhibitorok | |
| IL289534A (en) | Parp1 inhibitors | |
| EP3897631A4 (fr) | Dégradation ciblée de protéines | |
| HRP20220269T8 (hr) | Heterociklilamino-supstituirani triazoli kao modulatori rho-povezane protein kinaze | |
| EP3565846A4 (fr) | Agents thérapeutiques protéiques pour le traitement de cellules sénescentes | |
| EP3952914A4 (fr) | Procédés et compositions pour une dégradation de protéine ciblée | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| PL3917626T3 (pl) | Dwutrybowy radioznacznik i terapeutyk wiążący psma | |
| EA202091865A1 (ru) | Композиции и способы для снижения экспрессии tau | |
| IL260222A (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| PT3990005T (pt) | Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria | |
| PL3999119T3 (pl) | Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów | |
| DK3532059T3 (da) | Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer | |
| EP3886912A4 (fr) | Dendrimère pour thérapie et imagerie | |
| EA201791937A1 (ru) | Противовоспалительные полипептиды | |
| EP4013440A4 (fr) | Peptides thérapeutiques | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| MA71624A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| IL288090A (en) | Expression of antigen-binding proteins in the nervous system | |
| IL288237A (en) | Combination therapy | |
| EP4039328A4 (fr) | Agent soulageant la dysurie |